[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 350
1. Bai JG, Dang CX: [New classification for adenocarcinoma of the esophagogastric junction in China]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb;32(1):138-43
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New classification for adenocarcinoma of the esophagogastric junction in China].
  • OBJECTIVE: To determine the clinical application of the new classification of adenocarcinoma of esophagogastric junction (AEG).
  • RESULTS: Among the 203 patients that were up to the standard, 29 had adenocarcinoma of the distal esophagus (Type I), 80 had true carcinoma of cardia (Type II), and 94 had subcardial carcinoma (Type III).
  • CONCLUSION: Difference has been found in the clinicopathologic characteristics of the 3 types of adenocarcinoma of the esophagogastric junction.
  • [MeSH-major] Adenocarcinoma / classification. Esophageal Neoplasms / classification. Esophagogastric Junction / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344604.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE, Elston R, Eng C: Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev; 2006 Sep;15(9):1668-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction.
  • BACKGROUND AND AIM: The familial aggregation of Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction, jointly termed familial Barrett's esophagus, may represent a complex genetic trait.
  • METHODS: Information on gastroesophageal reflux symptoms, known risk factors for Barrett's esophagus, and family history of Barrett's esophagus and cancers, was collected at six hospitals using a structured questionnaire from probands with either long-segment Barrett's esophagus, adenocarcinoma of the esophagus, or adenocarcinoma of the gastroesophageal junction.
  • Upon review of medical records of the reportedly affected relatives, familial Barrett's esophagus was definitively determined in the case of 30 (7.3%) probands comprising 17 of 276 (6.2%) with Barrett's esophagus, 11 of 116 (9.5%) with adenocarcinoma of the esophagus, and 2 of 21 (9.5%) with adenocarcinoma of the gastroesophageal junction.
  • The diagnosis in the relative reported by the proband to be affected was found not to be Barrett's esophagus or adenocarcinoma in 15 (3.6%) cases.
  • There were no significant differences in age of disease onset, gender, race, or gastroesophageal reflux symptoms between definitive familial Barrett's esophagus probands and nonfamilial probands.
  • CONCLUSION: Familial Barrett's esophagus can be confirmed in 7.3% of persons presenting with Barrett's esophagus, adenocarcinoma of the esophagus, or adenocarcinoma of the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Esophagogastric Junction
  • [MeSH-minor] Aged. Body Mass Index. Female. Gastroesophageal Reflux / complications. Humans. Male. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985029.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA30722; United States / NIDDK NIH HHS / DK / DK002800; United States / NIDDK NIH HHS / DK / DK061426; United States / NIDDK NIH HHS / DK / DK070863; United States / NIGMS NIH HHS / GM / GM28356; United States / PHS HHS / / P30CAD43703; United States / NCI NIH HHS / CA / R25 CA094186
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Di Lauro L, Nunziata C, Arena MG, Foggi P, Sperduti I, Lopez M: Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer; 2007 Sep 3;97(5):593-7
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
  • This phase II study was designed to evaluate the activity and safety of a combination of irinotecan, docetaxel and oxaliplatin in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • The irinotecan, docetaxel and oxaliplatin combination chemotherapy is an active and well-tolerated novel regimen for treating metastatic gastric or GEJ adenocarcinoma and deserves further evaluation in randomised trials and in combination with molecular targeting agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction / drug effects. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):658-63 [14966088.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4543-8 [12454110.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):747-9 [10328099.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):371-9 [10448285.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1402-6 [16641896.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):221-31 [16770784.001]
  • [Cites] Future Oncol. 2006 Oct;2(5):603-20 [17026452.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):315-24 [17376598.001]
  • [Cites] Stat Med. 2001 Mar 30;20(6):859-66 [11252008.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1204-9 [15277259.001]
  • (PMID = 17667920.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2360369
  •  go-up   go-down


Advertisement
4. Leers JM, DeMeester SR, Chan N, Ayazi S, Oezcelik A, Abate E, Banki F, Lipham JC, Hagen JA, DeMeester TR: Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg; 2009 Sep;138(3):594-602; discussion 601-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus.
  • OBJECTIVE: The Siewert classification system differentiates between adenocarcinoma of the gastroesophageal junction and that of the distal esophagus.
  • METHODS: Records of all patients who underwent resection for adenocarcinoma of the distal esophagus or gastroesophageal junction from 1987 to 2007 were retrospectively reviewed.
  • Based on the endoscopic location of the epicenter of the tumor in relation to the gastroesophageal junction, tumors were categorized in 301 patients as being of the distal esophagus and in 208 as being of the gastroesophageal junction.
  • RESULTS: There were no significant differences in age, sex, or body mass index between patients with adenocarcinoma of the distal esophagus or gastroesophageal junction.
  • Patients with adenocarcinoma of the distal esophagus were more likely to have reflux symptoms (75% vs 53%, P < .0001) and peritumoral intestinal metaplasia (73% vs 51%, P < .0001) and be in a surveillance program (54% vs 9%, P = .0005) compared with patients with adenocarcinoma of the gastroesophageal junction.
  • However, the prevalence and location of nodal metastases was similar, and in node-positive patients mediastinal node involvement was present in more than 40% of the patients in each group (distal esophageal adenocarcinoma, 47%; gastroesophageal junction adenocarcinoma, 41%).
  • Survival was similar (5 years: distal esophageal adenocarcinoma, 45%; gastroesophageal junction adenocarcinoma, 38%; P = .14), as was the prevalence and type of recurrence.
  • CONCLUSION: The prevalence and distribution of lymph node metastases in patients with adenocarcinoma of the distal esophagus and gastroesophageal junction were similar, and after esophagectomy, there was no difference in overall survival or recurrence.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / mortality. Esophagogastric Junction / surgery. Neoplasm Recurrence, Local / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698841.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Yamamoto M, Baba H, Egashira A, Oki E, Ikebe M, Kakeji Y, Maehara Y: Adenocarcinoma of the esophagogastric junction in Japan. Hepatogastroenterology; 2008 Jan-Feb;55(81):103-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction in Japan.
  • BACKGROUND/AIMS: The prognosis of adenocarcinoma of the esophagogastric junction is worse than that in adenocarcinoma of other parts of the stomach.
  • In particular, the clinical features and prognosis of adenocarcinoma of the esophagogastric junction and the differences between Siewert's type II and III tumors in Japan were evaluated.
  • METHODOLOGY: We analyzed one hundred and forty patients with adenocarcinoma of the esophagogastric junction including one patient with a type I tumor, sixty-seven patients with type II tumors, and seventy-two patients with type III tumors.
  • RESULTS: The prognosis of patients with type III tumors was poorer in comparison to that of type II tumors in adenocarcinoma of the esophagogastric junction (p<0.05).
  • CONCLUSIONS: The prognosis of patients with lymph node metastasis of type III adenocarcinoma of the esophagogastric junction was found to be extremely poor.
  • [MeSH-major] Adenocarcinoma / mortality. Esophagogastric Junction. Stomach Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507087.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Hsiao HH, Yang SF, Liu YC, Yang MJ, Lin SF: Synchronous gastrointestinal stromal tumor and adenocarcinoma at the gastroesophageal junction. Kaohsiung J Med Sci; 2009 Jun;25(6):338-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous gastrointestinal stromal tumor and adenocarcinoma at the gastroesophageal junction.
  • We report the case of a 75-year-old man who had a concurrent gastrointestinal stromal tumor and adenocarcinoma at the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophagogastric Junction / pathology. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Stromal Tumors / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560999.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Number-of-references] 10
  •  go-up   go-down


7. Loaeza-del Castillo A, Villalobos-Pérez JJ: [Study of 30 years on the change in the frequency of esophageal squamous cell carcinoma, esophageal adenocarcinoma and adenocarcinoma of the esophagogastric union]. Rev Gastroenterol Mex; 2008 Jan-Mar;73(1):11-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of 30 years on the change in the frequency of esophageal squamous cell carcinoma, esophageal adenocarcinoma and adenocarcinoma of the esophagogastric union].
  • [Transliterated title] Estudio de 30 años sobre el cambio en la frecuencia de carcinoma epidermoide esofágico, adenocarcinoma esofágico y adenocarcinoma de la unión esofagogástrica.
  • OBJECTIVE: Our aim was to compare the frequency of esophageal adenocarcinoma cases (EA) and squamous cell carcinoma (SCC) cases in two study periods (1977-1988 vs. 1989-2006).
  • METHOD: Patients with esophageal cancer or adenocarcinoma of gastroesophageal junction (AGEJ) referred to the Nation al Institute of Medical Sciences and Nutrition "Salvador Zubirán" during 1989-2006 were included.
  • There was a significant association between gastroesophageal reflux disease (GERD) and EA (OR = 9.5; CI 95% 1.9-48.5, P = 0.0025), and also between GERD and AGEJ (OR 5.6; CI 95% 1.07-28.8, P = 0.03).
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology. Esophagogastric Junction

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18792668.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


8. Bar-Sela G, Tsalic M, Steiner M, Wollner M, Haim N: Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma. Anticancer Res; 2009 May;29(5):1853-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence following adjuvant chemotherapy without radiotherapy in completely resected stomach and gastroesophageal junction adenocarcinoma.
  • BACKGROUND: The gold standard of adjuvant treatment after surgical resection of adenocarcinoma of the stomach or gastroesophageal junction (GEJ) is chemoradiotherapy.
  • We retrospectively evaluated chemotherapy without radiotherapy in stomach and GEJ adenocarcinoma, using a combination of etoposide, adriamycin and cisplatin (modified EAP).
  • PATIENTS AND METHODS: Sixty-five patients with completely resected gastric or GEJ adenocarcinoma and positive regional lymph nodes were treated with modified EAP over an 8-year period.
  • [MeSH-major] Adenocarcinoma / drug therapy. Chemotherapy, Adjuvant. Neoplasm Recurrence, Local. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443416.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


9. Bai JG, Lv Y, Dang CX: Adenocarcinoma of the Esophagogastric Junction in China according to Siewert's classification. Jpn J Clin Oncol; 2006 Jun;36(6):364-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the Esophagogastric Junction in China according to Siewert's classification.
  • On the basis of the classification, this study aims to research into the clinicopathological characteristics and surgical modes of adenocarcinoma of the esophagogastric junction in China.
  • RESULTS: Among the 203 patients, there were 29 patients with adenocarcinoma of the distal esophagus (Type I); 80 patients with true carcinoma of cardia (Type II); and 94 patients with subcardial carcinoma (Type III).
  • [MeSH-major] Adenocarcinoma / classification. Esophageal Neoplasms / classification. Esophagectomy. Esophagogastric Junction. Lymph Node Excision. Stomach Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766566.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Nakamura T, Oguma H, Sasagawa T, Ota M, Kitamura Y, Yamamoto M: Left thoracoabdominal approach for adenocarcinoma of the esophagogastric junction. Hepatogastroenterology; 2008 Jul-Aug;55(85):1332-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left thoracoabdominal approach for adenocarcinoma of the esophagogastric junction.
  • BACKGROUND/AIMS: To evaluate usefulness of esophagogastrectomy via left thoracoabdominal (LT) approach for adenocarcinoma of the esophagogastric junction (AEG), the results of surgery stratified by Siewert's classification, were analyzed retrospectively.
  • METHODOLOGY: The tumor diameter, distance of the proximal tumor border from the esophagogastric junction, and length of the esophagus in the resected specimens of consecutive 171 AEG patients were measured.
  • The approach could not be determined by Siewert's classification, but by distance of proximal tumor border from the junction.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagogastric Junction. Gastrectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795683.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Ielpo B, Pernaute AS, Elia S, Buonomo OC, Valladares LD, Aguirre EP, Petrella G, Garcia AT: Impact of number and site of lymph node invasion on survival of adenocarcinoma of esophagogastric junction. Interact Cardiovasc Thorac Surg; 2010 May;10(5):704-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of number and site of lymph node invasion on survival of adenocarcinoma of esophagogastric junction.
  • Lymph node involvement in adenocarcinoma of the esophagogastric junction (EGJ) is similar to that of gastric cancer.
  • The impact on survival of the number and site of lymph nodes involved in a subgroup of patients undergone surgery for adenocarcinoma of EGJ is reported.
  • Sixty-four patients undergone transthoracic esophagectomy with two-field lymphadenectomy for adenocarcinoma of the EGJ were retrospectively assessed.
  • Classification of lymph node involvement in adenocarcinoma of the EGJ by gastric cancer criteria is adequate for prognostic purposes.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Esophageal Neoplasms / mortality. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
  • (PMID = 20154347.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Zhang J, Tian XY, Wu XJ, Zong XL, Wu J, Ji JF: [Role of papillomavirus in adenocarcinoma of esophagogastric junction]. Zhonghua Yi Xue Za Zhi; 2010 Aug 24;90(32):2259-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of papillomavirus in adenocarcinoma of esophagogastric junction].
  • OBJECTIVE: To determine if human papillomavirus (HPV) infection could be associated with the development of adenocarcinoma of esophagogastric junction (AEG).
  • [MeSH-major] Adenocarcinoma / virology. Esophageal Neoplasms / virology. Esophagogastric Junction / pathology. Papillomaviridae / pathogenicity. Stomach Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029672.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Fang WL, Wu CW, Chen JH, Lo SS, Hsieh MC, Shen KH, Hsu WH, Li AF, Lui WY: Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. Ann Surg Oncol; 2009 Dec;16(12):3237-44
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan.
  • BACKGROUND: The incidence of adenocarcinoma of the esophagogastric junction (AEG) is rapidly increasing.
  • [MeSH-major] Adenocarcinoma / classification. Esophageal Neoplasms / classification. Esophagogastric Junction / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19636628.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


15. del Genio A, Rossetti G, Maffettone V, Napolitano V, Brusciano L, del Genio G, Russo G, Limongelli P, Fiume I, Pizza F, Tolone S, Di Martino M: Gastroesophageal junction adenocarcinoma: what are the factors influencing long-term survival? Int Surg; 2006 May-Jun;91(3):174-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroesophageal junction adenocarcinoma: what are the factors influencing long-term survival?
  • The incidence of gastroesophageal junction adenocarcinoma is increasing.
  • The aim of our study was to report our experience in the treatment of gastroesophageal junction adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Esophageal Neoplasms / mortality. Esophagogastric Junction

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845860.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Rousseau M, Guevremont P, Chasen M, Spicer J, Eckert E, Alcindor T, Ades S, Ferri LE: The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? J Clin Oncol; 2009 May 20;27(15_suppl):9613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts undergoing neoadjuvant chemotherapy (TAX/CDDP/5FU Q3 weeks x3) for esophageal or GEJ adenocarcinoma at a single institution from 3/07-7/08 were identified from a prospective database.
  • CONCLUSIONS: Appropriately timed neoadjuvant chemotherapy with a highly effective regimen rapidly restores normal swallowing, maintains nutritional status, and obviates the need for ITF in patients with significant dysphagia from esophageal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ruhstaller T, Pless M, Schuller JC, Kranzbühler H, von Moos R, Moosmann P, Rauch D, Montemurro M, Schneider PM, Hess V: Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase lb-ll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06). J Clin Oncol; 2009 May 20;27(15_suppl):4570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with resectable, locally advanced squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the thoracic esophagus or gastroesophageal junction (staged by EUS, CT and PET scan) were treated with 2 cycles of induction chemotherapy (docetaxel 75mg/m2, cisplatin 75mg/m2 q3w and weekly cetuximab 250mg/m2), followed by concomitant chemo- immuno-radiation therapy (CIRT: docetaxel 20mg/m2, cisplatin 25mg/m2 and cetuximab 250mg/m2 weekly five times concomitant with 45 Gy radiotherapy in 25 fractions); followed by surgery 4-8 weeks later.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963079.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. El-Rayes BF, Patel B, Zalupski M, Hammad N, Shields A, Heilbrun L, Venkatramanamoorthy R, Philip P: A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer.
  • METHODS: The primary endpoint was time to progression (TTP) in patients with locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction treated with docetaxel, oxaliplatin and bevacizumab.
  • At this time, bevacizumab should not be used in gastric or gastroesophageal junction cancers outside of a clinical trial until its safety is well established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Khan G, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, Murthy SC, Mason DP, Rodriguez CP, Ives DI: Multimodality treatment for distal esophageal (DE) and gastroesophageal junction (GEJ) adenocarcinoma (ACA) with celiac lymph node (CLN) involvement. J Clin Oncol; 2009 May 20;27(15_suppl):4574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment for distal esophageal (DE) and gastroesophageal junction (GEJ) adenocarcinoma (ACA) with celiac lymph node (CLN) involvement.
  • : 4574 Background: CLN involvement is a predictor of poor outcome in patients (pts) with DE or GEJ ACA.
  • METHODS: We retrospectively identified all pts with DE or GEJ ACA, CLN involvement by EUS, CT or PET, and no evidence of distant hematogenous metastases, who were treated with the same CCRT and surgery protocol at the Cleveland Clinic.
  • DE (vs. GEJ) primary site predicted for better DMC (p < 0.001), FFR (p = 0.002), and OS (p = 0.025).
  • DMC, FFR, and OS were worse in pts with GEJ primaries, but were independent of how the CLN involvement was clinically identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963075.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Horgan AM, Darling G, Wong R, Visbal A, Guindi M, Jonker D, Liu G, Hornby J, Xu W, Knox JJ: Adjuvant sunitinib following chemoradiotherapy (CRT) and surgery for esophageal cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with LAEC of the thoracic esophagus or gastroesophageal junction, ECOG PS 0,1 and surgical candidates treated with: preoperative Irinotecan (65mg/m<sup>2</sup> initially, ammended to 50mg/m<sup>2</sup>) + Cisplatin (30mg/m<sup>2</sup>) on weeks 1,2,4,5,7,8 + concurrent conformal radiotherapy (50Gy/25 fractions) on weeks 4-8.
  • Median age 64 yr (43-71), male: 22, adenocarcinoma: squamous 22:6; 10 pts stage IIA, 5 IIB and 13 III.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962341.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Lin R, Chen Q, Fan N, Ye Y, Guo Z, Wang X, Liu J, Chen L: Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):e15642

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with previously untreated, advanced, unresectable, and histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction were randomly assigned to POF or IF regiment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962736.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kunz PL, de Bruin MA, Balise RR, Fisher GA, Ford JM: Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. J Clin Oncol; 2009 May 20;27(15_suppl):e15686

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience.
  • : e15686 Background: There is no single standard chemotherapy regimen for the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • METHODS: A single institution retrospective review of patients with metastatic gastric and GEJ adenocarcinoma treated with CF or CX was conducted.
  • Twenty-nine (64%) had gastric and 16 (36%) had GEJ cancers.
  • CONCLUSIONS: CF and CX are well tolerated and yield acceptable outcomes in high-risk metastatic gastric and gastroesophageal junction cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Manikyam Y, Hanna GG, Harte RJ, Henry PG, Houston RF, Eatock MM: Impact of socioeconomic status on treatment outcome in patients with advanced esophagogastric cancer in Northern Ireland. J Clin Oncol; 2009 May 20;27(15_suppl):e20531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of socioeconomic status on treatment outcome in patients with advanced esophagogastric cancer in Northern Ireland.
  • : e20531 Background: The survival advantage for combination chemotherapy in advanced gastroesophageal adenocarcinoma is well documented.
  • We report the impact of socioeconomic status on the outcome of ECF and ECX treatment in advanced gastroesophageal cancer patients in Northern Ireland between 2000 and 2007.
  • METHODS: All patients with advanced esophageal (O), gastric (G), or esophagogastric junction (OGJ) adenocarcinoma, receiving palliative chemotherapy from January 2000 to August 2007, were identified from our institutional database.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960981.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. de Bruin MA, Kunz PL, Sharma VB, Norton JA, Bastidas J, Chang DT, Koong AC, Koong AC, Balise RR, Ford JM, Fisher GA: Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. J Clin Oncol; 2009 May 20;27(15_suppl):e15674

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience.
  • : e15674 Background: The standard of care for the adjuvant treatment of resected gastric or gastroesophageal junction (GEJ) adenocarcinoma in the U.S. is post-operative 5FU and radiotherapy per the MacDonald regimen.
  • METHODS: A retrospective review was performed of patients at SCC with T2-T4 or node positive gastric or GEJ cancer who underwent surgery with curative intent, and then received the following treatment.
  • Thirty-nine had gastric and 10 had GEJ cancers.
  • CONCLUSIONS: Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine after curative resection of gastric and GEJ cancer was well tolerated and yielded survival results similar to historical data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962823.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ectors N, Driessen A, De Hertog G, Lerut T, Geboes K: Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? Arch Pathol Lab Med; 2005 Feb;129(2):183-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma?
  • This shift most likely reflects an increase in the incidence of gastroesophageal reflux.
  • If the above-mentioned etiopathologic links are correct, this could indicate that the so-called cardia adenocarcinomas are not related to H pylori infection and that they may instead be related to gastroesophageal reflux and eventually may not be considered to be "gastric" cancers.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15679417.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


26. Koike T, Ohara S, Inomata Y, Abe Y, Iijima K, Shimosegawa T: The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan. Inflammopharmacology; 2007 Apr;15(2):61-4
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for gastroesophageal junction adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan.
  • Gastroesophageal (GE) junction adenocarcinoma, including Barrett's adenocarcinoma, has been thought to be a complication of gastroesophageal reflux disease.
  • However, the relationship between H. pylori infection, gastric acid secretion and GE junction adenocarcinoma had not yet been investigated in Japan.
  • We demonstrated that the status of gastric acid secretion was higher in patients with GE junction adenocarcinoma than in patients with early gastric cancer (EGC), and that the level was the same in patients with RE and those with BE.
  • We also found that the prevalence of H. pylori infection in patients with GE junction adenocarcinoma was significantly lower than that in patients with EGC, although not as low as that in patients with RE and BE, suggesting that preservation of gastric acid secretion may be important for the development of GE junction adenocarcinoma in Japanese people, regardless of the presence of H. pylori infection.
  • [MeSH-major] Adenocarcinoma / complications. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / complications
  • [MeSH-minor] Esophageal Neoplasms / complications. Esophageal Neoplasms / ethnology. Esophageal Neoplasms / physiopathology. Esophagogastric Junction / physiopathology. Gastric Acid / secretion. Humans. Japan / epidemiology. Prevalence

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450443.001).
  • [ISSN] 0925-4692
  • [Journal-full-title] Inflammopharmacology
  • [ISO-abbreviation] Inflammopharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 42
  •  go-up   go-down


27. Palanivelu C, Prakash A, Parthasarathi R, Senthilkumar R, Senthilnathan PR, Rajapandian S: Laparoscopic esophagogastrectomy without thoracic or cervical access for adenocarcinoma of the gastroesophageal junction: an Indian experience from a tertiary center. Surg Endosc; 2007 Jan;21(1):16-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic esophagogastrectomy without thoracic or cervical access for adenocarcinoma of the gastroesophageal junction: an Indian experience from a tertiary center.
  • Esophagogastrectomy for the adenocarcinoma of the gastroesophageal (GE) junction has been a conventional treatment.
  • The aim of this study was to evaluate the outcome of laparoscopic esophagogastrectomy in the management of adenocarcinoma of the GE junction.
  • Indication for operation was adenocarcinoma of the GE junction in all patients.
  • CONCLUSION: In selected cases of adenocarcinoma of the GE junction, laparoscopic esophagogastrectomy offers as good as or better results than open operation in our institution with extensive advance endoscopic and open experience.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Esophagogastric Junction / surgery. Gastrectomy. Laparoscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031742.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Fumagalli U, de Carli S, de Pascale S, Rimassa L, Bignardi M, Rosati R: Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. Updates Surg; 2010 Aug;62(1):63-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival.
  • Treatment of adrenal metastases from cancer of the esophagogastric junction (EGJ) is not defined.
  • The aim of the present work is to analyze retrospectively our experience in treating patients with adrenal metastases from EGJ adenocarcinoma.
  • 102 patients with Siewert 1 or 2 EGJ adenocarcinoma underwent esophagectomy between May 2001 and Jan 2009.
  • Five patients were diagnosed an adrenal metastases from EGJ adenocarcinoma, synchronous (s) in one and metachronous (m) in four, in the latter 11 months (mean) after esophagectomy.
  • In conclusion, our experience indicates that patients with adrenal metastases from adenocarcinoma of the EGJ may benefit from adrenalectomy if the gland is the only site of metastasis beyond lymphnodal disease.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adrenalectomy. Esophagogastric Junction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845103.001).
  • [ISSN] 2038-131X
  • [Journal-full-title] Updates in surgery
  • [ISO-abbreviation] Updates Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Power DG, Reynolds JV: Localized adenocarcinoma of the esophagogastric junction--is there a standard of care? Cancer Treat Rev; 2010 Aug;36(5):400-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized adenocarcinoma of the esophagogastric junction--is there a standard of care?
  • Adenocarcinoma of the esophagogastric junction (AEG) is the most rapidly increasing tumour in the Western world.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Esophagogastric Junction. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20117883.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 119
  •  go-up   go-down


30. Tang LH, Klimstra DS: Barrett's esophagus and adenocarcinoma of the gastroesophageal junction: a pathologic perspective. Surg Oncol Clin N Am; 2006 Oct;15(4):715-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's esophagus and adenocarcinoma of the gastroesophageal junction: a pathologic perspective.
  • The etiology of Barrett's esophagus is understood poorly, but chronic gastroesophageal reflux disease is considered a major contributing factor.
  • Barrett's esophagus is associated with the development of adenocarcinoma of the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030269.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


31. Inomata Y, Koike T, Ohara S, Abe Y, Sekine H, Iijima K, Ariizumi K, Yamagishi H, Kitagawa Y, Imatani A, Shimosegawa T: Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status. Am J Gastroenterol; 2006 May;101(5):926-33
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status.
  • Gastroesophageal (GE) junction adenocarcinoma, including Barrett's adenocarcinoma, has been thought to be a complication of gastroesophageal reflux disease (GERD).
  • However, the relationship between H. pylori infection, gastric acid secretion, and GE junction adenocarcinoma has not yet been investigated in Japan.
  • METHODS: A total of 168 Japanese patients (RE alone: 80, short-segment BE (SSBE): 16, long-segment BE (LSBE): 20, GE junction adenocarcinoma: 12, distal early gastric cancer (EGC): 40; male/female = 106/62; mean age 61.5 yr) and 80 Japanese control subjects who had no localized lesions in the upper gastrointestinal tract (male/female = 43/37, mean age 58.1 yr) were enrolled for this study.
  • On the other hand, while the prevalence of H. pylori infection in patients with GE junction adenocarcinoma (58.3%) was significantly lower than that in patients with EGC (87.5%), it tended to be higher than that in patients with RE alone or BE.
  • The mean EGT value in patients with GE junction adenocarcinoma (3.94) was significantly higher than that in control subjects and patients with EGC (0.67), but it was comparable to that independent of the H. pylori infection status in patients with RE alone or BE.
  • CONCLUSION: Preservation of gastric acid secretion may be important for the development of GE junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / physiopathology. Esophageal Neoplasms / complications. Esophageal Neoplasms / physiopathology. Esophagitis, Peptic / physiopathology. Esophagogastric Junction. Gastric Acid / secretion. Helicobacter Infections / complications. Helicobacter pylori

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2006 May;101(5):934-6 [16696780.001]
  • (PMID = 16573782.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


32. Richards DA, Boehm KA, Anthony SP: Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs; 2007 Jul;16(7):1059-68
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
  • The incidence of distal gastric cancer is declining; however, there has been a rapid rise in the incidence of adenocarcinoma of the gastroesophageal junction, which is a more aggressive entity.
  • This review examines recent advances in the treatment of gastroesophageal junction adenocarcinoma and gastric cancer, newer agents and the potential agents that are in development, which can be logically applied to the treatment of this devastating disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Esophagogastric Junction / pathology. Female. Forecasting. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594189.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 56
  •  go-up   go-down


33. Sauvanet A, Mariette C, Thomas P, Lozac'h P, Segol P, Tiret E, Delpero JR, Collet D, Leborgne J, Pradère B, Bourgeon A, Triboulet JP: Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors. J Am Coll Surg; 2005 Aug;201(2):253-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors.
  • BACKGROUND: Resection for adenocarcinoma of the gastroesophageal junction (AGEJ) is associated with severe mortality and morbidity.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Esophagogastric Junction. Gastrectomy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038824.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, Shimoda T: Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol; 2008 Nov;23(11):1662-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan.
  • INTRODUCTION: A dramatic increase in incidence of adenocarcinoma of the esophagogastric junction (EGJ) over the past two decades has been reported in the West.
  • The aim of this study was to determine the incidence of adenocarcinoma of the EGJ in a cohort of consecutive patients operated on for gastric adenocarcinoma at a major cancer referral center in Japan.
  • METHOD: We reviewed pathological reports of all patients who underwent surgery for advanced gastric adenocarcinoma between 1962 and 2005 at the National Cancer Centre Hospital in Tokyo.
  • Adenocarcinoma of the EGJ was defined from images recorded for each patient, in accordance with the classification of Siewert and Stein.
  • The proportion of adenocarcinoma at the EGJ among operated gastric adenocarcinoma patients was compiled at five-year intervals and serial comparison made.
  • RESULTS: A total of 6953 patients with advanced gastric adenocarcinoma were operated on; adenocarcinoma of EGJ was found in 520 patients.
  • The overall proportion of adenocarcinoma of the EGJ increased from 2.3% (1962-1965) to 10.0% (2001-2005).
  • CONCLUSION: An increasing trend of adenocarcinoma of EGJ is observed in this study of patients operated on for gastric adenocarcinoma from 1962 to 2005 in a large tertiary referral center in Japan.
  • [MeSH-major] Adenocarcinoma / ethnology. Asian Continental Ancestry Group / statistics & numerical data. Esophageal Neoplasms / ethnology. Esophagogastric Junction / pathology. Hospitals / statistics & numerical data. Stomach Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol Hepatol. 2008 Nov;23(11):1627-8 [19120853.001]
  • (PMID = 19120859.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Chung JW, Lee GH, Choi KS, Kim DH, Jung KW, Song HJ, Choi KD, Jung HY, Kim JH, Yook JH, Kim BS, Jang SJ: Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification. Dis Esophagus; 2009;22(8):676-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification.
  • The incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing in Western countries.
  • We retrospectively reviewed the medical records of 16 811 patients diagnosed with esophageal squamous cell carcinoma (ESC, n= 1450) or gastric noncardiac adenocarcinoma (GNCA, n= 14 751) between 1992 and 2006.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222529.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Oñate-Ocaña LF, Milán-Revollo G, Aiello-Crocifoglio V, Carrillo JF, Gallardo-Rincón D, Brom-Valladares R, Herrera-Goepfert R, Dueñas-González A: Treatment of the adenocarcinoma of the esophagogastric junction at a single institution in Mexico. Ann Surg Oncol; 2007 Apr;14(4):1439-48
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of the adenocarcinoma of the esophagogastric junction at a single institution in Mexico.
  • BACKGROUND: Adenocarcinoma of the esophagogastric junction (EGJ) is rapidly increasing in the west.
  • METHODS: A retrospective cohort of patients suffering from EGJ adenocarcinoma treated from 1987 to 2000.
  • CONCLUSIONS: EGJ adenocarcinoma is a highly lethal neoplasia and the location after the Siewert' classification is not a prognostic factor.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235713.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF: Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol; 2007 Feb;14(2):306-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.
  • The aim of this study was to determine whether adequate staging revealed different prognostic factors or improved survival compared with patients with <15 nodes examined after R0 resection for GEJ cancer.
  • METHODS: A prospectively maintained database identified 366 patients with Siewert types II and III adenocarcinoma of the GEJ who underwent R0 resection without neoadjuvant therapy at a single institution.
  • CONCLUSIONS: Patients with GEJ cancer should undergo adequate lymphadenectomy to permit examination of >or=15 lymph nodes allowing the accurate identification of prognostic variables.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Lymph Node Excision / standards. Lymph Nodes / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091329.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR: Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol; 2009 Apr;16(4):1017-25
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center.
  • BACKGROUND: Despite a considerable number of randomized studies, the surgical approach to locally advanced adenocarcinoma of the esophagogastric junction (AEG) I and II is still discussed controversially.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Esophagogastric Junction / surgery. Esophagus / surgery. Stomach / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189186.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O: Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg; 2009 Jan;33(1):95-103
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center.
  • BACKGROUND: We clarified the incidence of adenocarcinoma of the esophagogastric junction (AEG) at a Japanese high-volume cancer center and its clinicopathological features between the Siewert subtypes.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958523.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, Walther B: Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg; 2008 Jun;32(6):1013-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.
  • BACKGROUND: Adenocarcinoma at the gastroesophageal junction may be regarded as of esophageal or of gastric origin, and tumor removal may follow the principles of esophagectomy or extended gastrectomy.
  • METHODS: Baseline patient and tumor characteristics were collected, and tumors were categorized according to Siewert's classification (I, II, or III) of gastroesophageal junction tumors.
  • CONCLUSIONS: Provided that adequate tumor dissection is performed, patients with adenocarcinoma at the gastroesophageal junction can be resected and reconstructed using the principles for esophagectomy or extended gastrectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery


41. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D: Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol; 2006 Feb 1;24(4):663-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
  • We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination.
  • Patients with histologic proof of gastric or gastroesophageal junction adenocarcinoma with a Karnofsky performance status (KPS) of > or = 70% and near-normal organ function were eligible.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


42. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol; 2007 Mar;18(3):510-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
  • BACKGROUND: The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • PATIENTS AND METHODS: Untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received cetuximab at an initial dose of 400 mg/m(2) intravenously (i.v.) followed by weekly doses of 250 mg/m(2), CPT 11 180 mg/m(2) i.v. on day 1, LFA 100 mg/m(2) i.v. followed by 5-FU 400 mg/m(2) i.v. bolus, and 600 mg/m(2) i.v.
  • RESULTS: Thirty-eight patients were enrolled (median age 63.5 years, range 39-83; median Karnofsky performance status 90, range 70-100; stomach 89.5% and GEJ 10.5%; locally advanced disease 13.2% and metastatic disease 86.8%).
  • CONCLUSIONS: The combination of cetuximab and FOLFIRI is active in gastric and GEJ adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164226.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


43. Di Lauro L, Giacinti L, Arena MG, Sergi D, Fattoruso SI, Giannarelli D, Lopez M: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res; 2009;28:34
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
  • BACKGROUND: This phase II study was designed to evaluate the activity and safety of a combination of epirubicin, oxaliplatin and docetaxel in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • CONCLUSION: The combination of epirubicin, oxaliplatin and docetaxel was found to be effective and well tolerated in patiens with metastatic gastric or GEJ adenocarcinoma and maybe an appropriate regimen to be used in the neoadjuvant setting and with molecularly targeted agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Oncologist. 2008 Jul;13(7):794-806 [18614586.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):658-63 [14966088.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Natl Cancer Inst. 1990 Jun 20;82(12):1046-50 [2348469.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1644-9 [15856038.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):190-4 [16012522.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1498-502 [15956036.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):959-63 [16552439.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] Future Oncol. 2006 Oct;2(5):603-20 [17026452.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):182-94 [18093827.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4543-8 [12454110.001]
  • (PMID = 19267943.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2657908
  •  go-up   go-down


44. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol; 2006 Nov 20;24(33):5201-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
  • We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma.
  • PATIENTS AND METHODS: Forty-seven patients with metastatic or unresectable gastric/GEJ adenocarcinoma were treated with bevacizumab 15 mg/kg on day 1, irinotecan 65 mg/m2, and cisplatin 30 mg/m2 on days 1 and 8, every 21 days.
  • RESULTS: Patient characteristics were as follows: median age 59 years (range, 25 to 75); Karnofsky performance status 90% (70% to 100%); male:female, 34:13; and gastric/GEJ, 24:23.
  • CONCLUSION: Bevacizumab can be safely given with chemotherapy even with primary gastric and GEJ tumors in place.
  • Further development of bevacizumab in gastric and GEJ cancers is warranted.
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114652.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01 CM62206; United States / NCI NIH HHS / CA / U01 CA099168-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


45. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A: A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs; 2006 Jul;24(4):353-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.
  • We studied sequential paclitaxel and bryostatin-1 in patients with untreated, advanced gastric adenocarcinoma.
  • METHODS: Patients with histologic proof of gastric or gastroesophageal junction adenocarcinoma with advanced, measurable cancers were eligible.
  • CONCLUSIONS: Sequential paclitaxel plus bryostatin-1 resulted in a superior response rate than would be expected of paclitaxel alone in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Esophageal Neoplasms / drug therapy. Esophagogastric Junction / pathology. Macrolides / administration & dosage. Macrolides / therapeutic use. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683077.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U10 CA 045809-15; United States / NCI NIH HHS / CM / N01-CM-1703
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


46. Uncu D, Ozdemir NY, Aksoy S, Abali H, Oksuzoglu BC, Budakoglu B, Yildiz R, Aslan N, Zengin N: Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma. Asian Pac J Cancer Prev; 2010;11(6):1493-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
  • PATIENTS AND METHODS: Between May 2005 and Dec 2008, 65 curatively resected gastric and gastroesophageal junction adenocarcinoma patients (stage III in 38 and stage IV M0 in 27) received chemotherapy including 50 mg/m2 cisplatin, 200 mg/m2 iv folinic acid, 5-FU 400 mg/m2 iv bolus followed by 5-FU 1600 mg/m2 46h-continuous infusion (CFF) bi-weekly.
  • CONCLUSION: Bi-weekly CFF chemotherapy followed by continuous 5-FU infusion during radiotherapy is an effective and tolerable regimen for locally advanced operated gastric and gastroesophageal junction adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction. Neoplasm Recurrence, Local / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21338186.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


47. Kimura A, Hiramatsu K, Sakuragawa T, Ito T, Otsuji H, Tsuchiya T, Hara T, Maeda T, Tanaka H, Machiki Y, Hosoya J, Kojima T, Kato K: [A case showing a complete response by weekly paclitaxel associated with severe empyema and mediastinal abscess caused by reduction of a recurrent lung metastatic tumor originating from adenocarcinoma of the esophagogastric junction after primary operation]. Gan To Kagaku Ryoho; 2010 Feb;37(2):303-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case showing a complete response by weekly paclitaxel associated with severe empyema and mediastinal abscess caused by reduction of a recurrent lung metastatic tumor originating from adenocarcinoma of the esophagogastric junction after primary operation].
  • The patient was a 57-year-old man who presented with cancer of the esophagogastric junction.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Empyema, Pleural / complications. Esophageal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Esophagectomy. Esophagogastric Junction / pathology. Gastrectomy. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154490.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


48. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd: Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol; 2010 Jun 20;28(18):2947-51
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
  • A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ).
  • PATIENTS AND METHODS: Forty-four chemotherapy-naïve patients with Eastern Cooperative Oncology Group performance status 0 or 1, of whom 80% had metastatic disease and two thirds had poorly differentiated gastric or GEJ adenocarcinoma, were enrolled.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagogastric Junction / drug effects. Esophagogastric Junction / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):481-7 [12181402.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):55-63 [17095207.001]
  • [Cites] Clin Lung Cancer. 2007 May;8(6):396-8 [17562243.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3217-23 [17664469.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4836-42 [18676756.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3129-40 [18852116.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1280-9 [19171708.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):666-73 [19153121.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4274-80 [19652055.001]
  • [CommentIn] J Clin Oncol. 2010 Jun 20;28(18):2937-8 [20458025.001]
  • (PMID = 20458043.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA017145; United States / NCRR NIH HHS / RR / UL1 RR025741; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / U10 CA015488
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Taxoids; 15H5577CQD / docetaxel; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2903332
  •  go-up   go-down


49. Parfitt JR, Miladinovic Z, Driman DK: Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002. Can J Gastroenterol; 2006 Apr;20(4):271-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada -- an epidemiological study from 1964-2002.
  • BACKGROUND: The increasing incidence of esophageal and proximal gastric (cardia) adenocarcinoma and the decreasing incidence of distal gastric (antropyloric) adenocarcinoma has been documented in several populations.
  • RESULTS: The incidence of adenocarcinoma of the distal esophagus increased in men and women (average annual increase of 9.5% in men; 4.3% in women).
  • The incidence of adenocarcinoma of the cardia increased in men and women (average annual increase of 7.3% in men; 5.8% in women).
  • The incidence of antropyloric adenocarcinoma increased in men and women (average annual increase of 4.4% in men; 5.3% in women).
  • CONCLUSIONS: There has been a significant increase in the incidence of adenocarcinoma around the gastroesophageal junction in men over the 39-year study period.
  • The increase in incidence of distal gastric adenocarcinoma is unexpected and may relate to a reclassification phenomenon, immigration trends in Ontario and a rising incidence of diffuse/signet ring cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Esophagogastric Junction. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1082-6 [11099062.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):290 [15737017.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Can J Public Health. 2004 Jan-Feb;95(1):16-20 [14768735.001]
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] BMJ. 2004 Aug 21;329(7463):420 [15321897.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):440-3 [2206952.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):275-8 [1467774.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):411-5 [7841063.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] Prev Med. 1997 Jul-Aug;26(4):534-41 [9245676.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Health Rep. 1998 Spring;9(4):31-7(Eng); 31-8(Fre) [9836878.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Apr;13(4):356-62 [9641297.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1800-2 [9772034.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • (PMID = 16609756.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2659904
  •  go-up   go-down


50. Yonemura Y, Kojima N, Kawamura T, Tsukiyama G, Bandou E, Sakamoto N, Tsubosa Y, Sato H: Treatment results of adenocarcinoma of the gastroesophageal junction. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):475-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of adenocarcinoma of the gastroesophageal junction.
  • METHODOLOGY: In this study 297 resectable adenocarcinomas arising around the GE junction, that had their center within 5cm oral and aboral of the anatomical GE junction, were analyzed.
  • They were subdivided into those with the tumor center located more than 1cm above the GE junction (Type 1, N = 7), those with the tumor center located within 1cm oral and 2cm aboral of the GE junction (Type 2) and those with the tumor center 2cm below the junction (Type 3).
  • RESULTS: Esophageal invasion distance of 83 among 84 Type 2A and 3A tumors limited within 5cm from the GE junction.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613391.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 16
  •  go-up   go-down


51. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT: The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer; 2006 Mar 1;106(5):1017-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
  • BACKGROUND: The survival of patients with locoregional adenocarcinoma of the esophagus or the esophagogastric junction (EGJ) who receive preoperative chemoradiation is reported to be better among patients who achieve a pathologic complete response than among patients who have residual tumor, including lymph node (LN) metastasis.
  • CONCLUSIONS: The current results suggested that the number of LNs with metastasis is an independent prognostic factor in patients with residual adenocarcinoma of the esophagus or the EGJ after preoperative chemoradiation.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Lymphatic Metastasis. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Esophagectomy. Esophagogastric Junction / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456809.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Tepper JE: Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma? Gastrointest Cancer Res; 2008 Jul;2(4 Suppl):S2-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma?
  • There have been very few treatment-related studies specifically addressing adenocarcinomas of the gastroesophageal junction (GEJ).
  • Studies addressing esophageal cancer have a larger percentage of patients with GEJ adenocarcinomas than do the primary gastric trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Br J Cancer. 1989 Nov;60(5):739-44 [2508737.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1249-54 [6491703.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • (PMID = 19343142.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2661553
  •  go-up   go-down


53. Chandrasoma P: What is adenocarcinoma of the esophagogastric junction? Am J Gastroenterol; 2008 Feb;103(2):492-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is adenocarcinoma of the esophagogastric junction?
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Esophagogastric Junction. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Gastroenterol. 2007 Aug;102(8):1596-602 [17459024.001]
  • (PMID = 18289219.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


54. Rizk NP, Tang L, Adusumilli PS, Bains MS, Akhurst TJ, Ilson D, Goodman K, Rusch VW: Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol; 2009 Jul;4(7):875-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
  • INTRODUCTION: We have previously shown that in early clinical stage esophageal adenocarcinoma, a positron emission tomography standardized uptake values (PET SUVmax) of <4.5 is associated with earlier pathologic stage and predicts better survival.
  • In this study, we analyze the impact of the pretreatment PET SUVmax in patients with locally advanced esophageal adenocarcinoma who undergo preoperative chemoradiotherapy.
  • METHODS: We performed a retrospective analysis, selecting patients with adenocarcinoma of the esophagus who had a pretreatment PET scan and who received chemoradiotherapy before esophagectomy.
  • CONCLUSIONS: Although the initial PET SUVmax does not predict survival in patients with locally advanced esophageal adenocarcinoma who receive preoperative chemoradiotherapy, patients with a high initial SUVmax respond better to preoperative therapy.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Esophageal Neoplasms / radionuclide imaging. Esophagogastric Junction / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19487968.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


55. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J: Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer; 2006 Aug 21;95(4):450-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
  • A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12 mg m(-2) over 30 min every 21 days.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / metabolism. Esophagogastric Junction. Glutarates / therapeutic use. Quinazolines / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma. Adult. Aged. Aged, 80 and over. Antineoplastic Agents. Female. Humans. Isoindoles. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1901-11 [11448903.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):653-8 [10995874.001]
  • [Cites] Int J Colorectal Dis. 2002 Jan;17(1):46-9 [12018454.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:13-22 [12401661.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):815-9 [12610179.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6004-7 [14522928.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):894-902 [14982966.001]
  • [Cites] Methods Mol Biol. 2004;281:91-103 [15220523.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Clin Chem. 1993 Feb;39(2):263-71 [8432015.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cell Struct Funct. 1995 Jun;20(3):191-7 [7586009.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5487-95 [16061865.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6957-65 [16145066.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):203-7 [16333305.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2898-904 [12782596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Jun;19(2):189-95 [10965817.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • (PMID = 16880795.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid; 0 / Antineoplastic Agents; 0 / Glutarates; 0 / Isoindoles; 0 / Quinazolines
  • [Other-IDs] NLM/ PMC2360664
  •  go-up   go-down


56. Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, Rampone B, Roviello F: Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg; 2007 Aug;134(2):378-85
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node involvement in advanced gastroesophageal junction adenocarcinoma.
  • OBJECTIVE: The prognosis of gastroesophageal junction adenocarcinoma is unquestionably related to the extent of nodal involvement; nonetheless, few studies deal with the pattern of lymph node spread and specifically analyze the prognostic value of the site of metastasis.
  • The present study was aimed at evaluating these key aspects in advanced gastroesophageal junction adenocarcinoma.
  • METHODS: Of 219 patients consecutively operated on for gastroesophageal junction adenocarcinoma at the Department of General Surgery and Surgical Oncology, University of Siena, and at the Department of General Surgery, University of Verona, 143 pT2-4 tumors not submitted to prior chemoradiation were analyzed according to the Japanese Gastric Cancer Association pN staging system.
  • CONCLUSIONS: In advanced gastroesophageal junction adenocarcinoma, the high frequency of nodal metastases and the related unfavorable long-term outcome achieved by means of surgical intervention alone are indicative of the need for aggressive multimodal treatment along with surgical intervention to improve long-term results.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662776.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT: Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res; 2005 Mar 15;11(6):2229-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
  • PURPOSE: The survival of patients with local-regional adenocarcinoma of the esophagus or esophagogastric junction (EGJ) treated with preoperative chemoradiation is much better in patients with pathologic complete response than those with residual tumor.
  • EXPERIMENTAL DESIGN: We studied 412 consecutive patients with esophageal or EGJ adenocarcinoma treated with chemoradiation followed by esophagectomy (193 patients) or surgery alone (219 patients).
  • CONCLUSIONS: Our study showed that patients with esophageal or EGJ adenocarcinoma who have signet-ring cell or mucinous histology benefited substantially from preoperative chemoradiation and esophagectomy.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788671.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E, Spanish Cooperative Group for Digestive Tumor Therapy: Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1430-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
  • PURPOSE: To determine in a Phase II trial whether preoperative irinotecan-cisplatin (IC) followed by concurrent IC therapy and radiotherapy (IC/RT) improved outcome in patients with resectable, locally advanced gastric adenocarcinoma (GC) or esophagogastric junction cancer (EGJC).
  • [MeSH-major] Adenocarcinoma. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms. Esophagogastric Junction. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540072.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


59. Jatoi A, Nguyen PL, Foster N, Sun D, Stella PJ, Campbell M, Tschetter LK, Dakhil SR, Mailliard JA, Nikcevich DA: Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. J Support Oncol; 2007 Jan;5(1):41-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma.
  • Do these IL-1 beta genetic polymorphisms predispose patients with gastric and gastroesophageal cancer to the anorexia/weight loss syndrome?
  • This study focused on 44 patients with metastatic gastric and gastroesophageal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Anorexia / genetics. Esophagogastric Junction. Interleukin-1beta / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics. Weight Loss / genetics

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265786.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1beta
  •  go-up   go-down


60. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF: Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg; 2007 Jul;246(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.
  • OBJECTIVE: To determine whether the length of esophageal resection or the operative approach influences outcome for patients with adenocarcinoma of the gastroesophageal junction (GEJ).
  • SUMMARY BACKGROUND DATA: While R0 resection remains the mainstay of curative treatment of patients with GEJ cancer, the optimal length of esophageal resection remains controversial.
  • METHODS: Patients with Siewert I, II, or III adenocarcinoma who underwent complete gross resection without neoadjuvant therapy were identified from a prospectively maintained database.
  • CONCLUSIONS: In patients not receiving neoadjuvant therapy, the goal for patients with adenocarcinoma of the GEJ should be R0 resection including at least 15 lymph nodes, preferably with 5 cm of grossly normal in situ proximal esophagus for those with <or=6 positive lymph nodes.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagogastric Junction

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Feb 15;103(4):702-7 [15641033.001]
  • [Cites] J Am Coll Surg. 2004 Dec;199(6):880-6 [15555971.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):810-4 [11087650.001]
  • [Cites] Surgery. 2001 Jan;129(1):103-9 [11150040.001]
  • [Cites] Dis Esophagus. 2001;14(1):32-6 [11422303.001]
  • [Cites] Dis Esophagus. 2001;14(2):104-9 [11553218.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):520-30; discussion 530-1 [11573045.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1223-9 [11953876.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):419-22 [11995464.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1156-63 [12190682.001]
  • [Cites] Dig Surg. 2002;19(4):269-74; discussion 275 [12207069.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):588-93 [12943624.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3647-50 [14512396.001]
  • [Cites] BMJ. 2003 Nov 22;327(7425):1192-7 [14630753.001]
  • [Cites] J Am Coll Surg. 2004 Jan;198(1):42-50 [14698310.001]
  • [Cites] Am J Gastroenterol. 2004 Mar;99(3):419-24 [15056079.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] Br J Surg. 1979 Sep;66(9):609-12 [497643.001]
  • [Cites] Am J Surg. 1980 May;139(5):711-3 [7468923.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):173-6 [3947154.001]
  • [Cites] Ann Surg. 1986 Feb;203(2):188-95 [3947155.001]
  • [Cites] Ann Surg. 1987 Feb;205(2):189-94 [3813689.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] Eur J Surg Oncol. 1992 Jun;18(3):282-6 [1607041.001]
  • [Cites] J Surg Oncol. 1993 May;53(1):60-3 [8479199.001]
  • [Cites] Am J Surg. 1995 Mar;169(3):316-9 [7879834.001]
  • [Cites] Hepatogastroenterology. 1995 Feb;42(1):37-42 [7782032.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):873-7 [8847038.001]
  • [Cites] Aust N Z J Surg. 1996 Nov;66(11):734-7 [8918379.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 May;113(5):836-46; discussion 846-8 [9159617.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):678-83; discussion 683-5 [9230808.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Dec;114(6):948-55; discussion 955-6 [9434690.001]
  • [Cites] Am J Surg. 1998 Sep;176(3):286-90 [9776161.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):352-7 [9783780.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Eur J Surg. 1998 Oct;164(10):759-64 [9840305.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jun;15(6):769-73 [10431857.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):594-601 [10589596.001]
  • (PMID = 17592282.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1899203
  •  go-up   go-down


61. Debes JD, Lagarde SM, Hulsenboom E, Sillevis Smitt PA, ten Kate FJ, Sulter GA, van Lanschot JJ: Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction. Dig Surg; 2007;24(5):395-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction.
  • In this report we describe a male patient adenocarcinoma of the gastroesophageal junction and PCD with anti-Yo antibodies.
  • To our knowledge, this is only the third report of PCD with positive anti-Yo antibodies in an esophageal tumor and the first report in a tumor of the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / immunology. Esophageal Neoplasms / immunology. Esophagogastric Junction. Nerve Tissue Proteins / immunology. Paraneoplastic Cerebellar Degeneration / immunology

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • Genetic Alliance. consumer health - Paraneoplastic cerebellar degeneration.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785986.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CDR2 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


62. Barbour AP, Rizk NP, Gerdes H, Bains MS, Rusch VW, Brennan MF, Coit DG: Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg; 2007 Oct;205(4):593-601
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction.
  • BACKGROUND: Endoscopic ultrasound (EUS) is the most accurate locoregional staging tool for gastroesophageal junction (GEJ) adenocarcinoma, and it may allow pretreatment risk stratification.
  • The purpose of this study was to compare preoperative EUS staging with postoperative pathologic staging and to assess the ability of EUS to predict survival after resection for GEJ adenocarcinoma.
  • STUDY DESIGN: Patients with GEJ adenocarcinoma, who had preoperative staging with EUS followed by resection, were identified from a prospectively maintained database.
  • RESULTS: From 1985 through 2003, 209 patients underwent preoperative EUS followed by surgery without neoadjuvant therapy for GEJ adenocarcinoma.
  • In addition, EUS is predictive of outcomes after complete gross resection without neoadjuvant treatment for GEJ adenocarcinoma and identifies a high-risk population that might benefit from preoperative therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Endosonography. Esophageal Neoplasms / pathology. Esophagogastric Junction. Neoplasm Staging. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903735.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol; 2007 Oct;18(10):1673-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
  • RESULTS: Sixty patients were enrolled: 24 had locally advanced (LA) tumors and 36 had metastatic disease.
  • Twenty-three LA patients underwent secondary surgical resection (96%); complete resection was achieved in 87%.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660494.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


64. van Dekken H, Wink JC, Vissers KJ, van Marion R, Koppert LB, Tilanus HW, Siersema PD, Tanke HJ, Szuhai K, Hop WC: Genomic analysis of early adenocarcinoma of the esophagus or gastroesophageal junction: tumor progression is associated with alteration of 1q and 8p sequences. Genes Chromosomes Cancer; 2006 May;45(5):516-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic analysis of early adenocarcinoma of the esophagus or gastroesophageal junction: tumor progression is associated with alteration of 1q and 8p sequences.
  • Early (T1 stage) adenocarcinoma of the esophagus or gastroesophageal junction is a potentially curable disease.
  • Comparative genomic hybridization with a genomewide 3,500-element BAC-PAC array revealed a characteristic gastroesophageal adenocarcinoma pattern of changes, with losses on chromosome arms 4pq, 5q, 8p, 9p, 17p, and 18q and gains on 1q, 6p, 7pq, 11q, 15q, 17q, and 20pq.
  • These DNA clones can be considered genomic markers for the aggressive behavior of early esophageal and gastroesophageal junction adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 8. Esophageal Neoplasms / genetics. Esophagogastric Junction / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc
  • (PMID = 16479570.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Keeney S, Bauer TL: Epidemiology of adenocarcinoma of the esophagogastric junction. Surg Oncol Clin N Am; 2006 Oct;15(4):687-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of adenocarcinoma of the esophagogastric junction.
  • The incidence of adenocarcinoma of the esophagogastric junction has increased rapidly in the later half of the twentieth century in the United States and most western countries.
  • Although squamous cell carcinoma of the esophagus used to predominate, adenocarcinoma of the distal esophagus and esophagogastric junction now accounts for more than half of new diagnoses in western countries.
  • These recent epidemiologic shifts have led to controversy regarding the etiology and treatment of adenocarcinoma of the esophagogastric junction.
  • Uncertainty still exists with regards to nomenclature and classification, risk factors, treatment, and screening and surveillance of esophagogastric adenocarcinoma.
  • This article examines the epidemiology and etiologies of adenocarcinoma of the esophagogastric junction.
  • [MeSH-major] Adenocarcinoma / epidemiology. Esophageal Neoplasms / epidemiology. Esophagogastric Junction / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030267.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


66. Yee YK, Wong BC: Adenocarcinoma of the esophagogastric junction: do we see more or less? J Gastroenterol Hepatol; 2008 Nov;23(11):1627-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: do we see more or less?
  • [MeSH-major] Adenocarcinoma / ethnology. Esophageal Neoplasms / ethnology. Esophagogastric Junction / pathology. Stomach Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Gastroenterol Hepatol. 2008 Nov;23(11):1662-5 [19120859.001]
  • (PMID = 19120853.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Australia
  •  go-up   go-down


67. Baccari P, Castoldi R, Bisagni P, Bissolotti G, Orsenigo E, Di Palo S, Casiraghi T, Carlucci M, Staudacher C: [Minimally invasive esophagectomy for adenocarcinoma of the lower esophagus and the gastroesophageal junction]. Suppl Tumori; 2005 May-Jun;4(3):S129
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimally invasive esophagectomy for adenocarcinoma of the lower esophagus and the gastroesophageal junction].
  • [Transliterated title] Esofagectomia mininvasiva per adenocarcinoma siewert i della giunzione gastroesofagea.
  • BACKGROUND: Adenocarcinoma of lower esophagus and GEJ shows worldwide an increasing incidence.
  • PATIENT AND METHODS: In the video we report the case of a 79 years old man with Siewert I adenocarcinoma of GEJ, who was submitted to a 3-stage minimally invasive esophagectomy by laparoscopy, right thoracoscopy and cervicotomy.
  • After extraction of the specimen through a small abdominal incision, the stomach was pulled up to the neck and esophagogastric anastomosis with the Orringer technique was constructed through a left cervicotomy.
  • Pathology showed pT3 pN1 G3 adenocarcinoma.
  • CONCLUSIONS: The minimally invasive approach to adenocarcinoma of the lower esophagus, in center with expertise in minimally invasive surgical technique, is feasible and safe.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagogastric Junction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437948.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


68. Takahashi M, Koeda K, Fujiwara H, Chiba T, Sasaki A, Wakabayashi G: [Five cases of advanced gastroesophageal junction adenocarcinoma successfully treated with chemoradiotherapy followed by curative resection]. Gan To Kagaku Ryoho; 2010 Nov;37(11):2169-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Five cases of advanced gastroesophageal junction adenocarcinoma successfully treated with chemoradiotherapy followed by curative resection].
  • We reviewed five patients with advanced gastroesophageal cancer who were successfully treated with chemoradiotherapy followed by a curative resection.
  • Patients with histologically-documented adenocarcinoma of the gastroesophageal junction were eligible.
  • The obvious chemotherapeutic efficacy of the present regimen suggested that it may be a good treatment option for advanced gastroesophageal cancers.
  • [MeSH-major] Adenocarcinoma / therapy. Esophagogastric Junction. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084820.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


69. Bîrlă R, Iosif C, Mocanu A, Gîndea C, Hoară P, Panaitescu E, Constantinoiu S: [Long-term survival after eso-gastrectomy for esophagogastric junction adenocarcinoma--prospective study]. Chirurgia (Bucur); 2008 Nov-Dec;103(6):635-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival after eso-gastrectomy for esophagogastric junction adenocarcinoma--prospective study].
  • [Transliterated title] Supravieţuirea la distantă după esogastrectomie pentru adenocarcinom de joncţiune esogastrică--studiu prospectiv.
  • Detection of the esophagogastric junction adenocarcinoma in symptomatic stage determine a low survival.
  • The aim of the study was to identify the prognostic factors after eso-gastrectomy for esophagogastric junction adenocarcinoma.
  • In locally advanced esophagogastric junction adenocarcinoma, the frequency of lymph nodes metastasis (81%) especially in patients with tumoral type III and unfavorable results of surgical treatment as unique therapeutically method show the necessity of a multimodal approach pre and post-operatory by using selection methods with a good prediction of neoadjuvant treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Esophagogastric Junction. Gastrectomy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274907.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


70. Lehrbach DM, Cecconello I, Ribeiro Jr U, Capelozzi VL, Ab'saber AM, Alves VA: Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. Arq Gastroenterol; 2009 Oct-Dec;46(4):315-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions.
  • CONTEXT: Esophagogastric junction adenocarcinoma has an aggressive behavior, and TNM (UICC) staging is not always accurate enough to categorize patient's outcome.
  • OBJECTIVES: To evaluated p53, cyclin D1 and Bcl-2 immunoexpressions in esophagogastric junction adenocarcinoma patients, without Barrett's esophagus, and to compared to clinicopathological characteristics and survival rate.
  • METHODS: Tissue sections from 75 esophagogastric junction adenocarcinomas resected from 1991 to 2003 were analyzed by immunohistochemistry for p53, cyclin D1 and Bcl-2 using streptavidin-biotin-peroxidase method.
  • [MeSH-major] Cyclin D1 / analysis. Esophageal Neoplasms / metabolism. Esophagogastric Junction. Proto-Oncogene Proteins c-bcl-2 / analysis. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232013.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


71. Wijnhoven BP, Pignatelli M, Dinjens WN, Tilanus HW: Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol; 2005 Nov 1;92(2):116-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction.
  • We studied the in vivo expression and cellular localization of p120ctn in adenocarcinomas of the gastroesophageal junction.
  • CONCLUSIONS: Abnormal p120ctn expression is frequently seen in adenocarcinomas of the gastroesophageal junction, and may be a useful as a prognostic marker in these tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion Molecules / metabolism. Esophageal Neoplasms / metabolism. Esophagogastric Junction. Lymph Nodes / pathology. Phosphoproteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16231374.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Phosphoproteins; 0 / delta catenin
  •  go-up   go-down


72. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, Asmar L: Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol; 2008 Jan;19(1):104-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
  • PATIENTS AND METHODS: Patients with untreated stage IV GC or adenocarcinoma of the gastroesophageal junction (AGEJ) received docetaxel 60 mg/m(2) followed by oxaliplatin 130 mg/m(2) on day 1 of each 21-day cycle until progression or unacceptable toxicity.
  • RESULTS: Baseline characteristics (N = 71): median age 59 years, 72% male, 51% esophagogastric junction cancer, and Eastern Cooperative Oncology Group performance status of zero, one, two were 42%, 51%, 7%, respectively.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897959.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7487-88-9 / Magnesium Sulfate; 7S5I7G3JQL / Dexamethasone; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


73. Dafnios N, Anastasopoulos G, Marinis A, Polydorou A, Gkiokas G, Fragulidis G, Athanasopoulos P, Theodosopoulos T: Esophagopericardial fistula as a rare complication after total gastrectomy for cancer. World J Surg Oncol; 2009;7:58
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE PRESENTATION: We present a case of an esophagopericardial fistula as a rare complication in a 53-year-old male patient, 7 months after total gastrectomy for an adenocarcinoma of the esophagogastric junction.
  • [MeSH-major] Esophageal Fistula / etiology. Esophageal Neoplasms / surgery. Esophagogastric Junction. Fistula / etiology. Gastrectomy / adverse effects. Pericardium. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Fistulas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Nov;52(5):689-91 [11060204.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3292-4 [11095358.001]
  • [Cites] Chest. 1972 Dec;62(6):728-31 [4635423.001]
  • [Cites] J Thorac Cardiovasc Surg. 1973 Mar;65(3):458-61 [4686662.001]
  • [Cites] JAMA. 1974 Feb 25;227(8):939 [4405867.001]
  • [Cites] J Thorac Cardiovasc Surg. 1974 Apr;67(4):590-2 [4818535.001]
  • [Cites] Chest. 1974 Dec;66(6):731-3 [4426208.001]
  • [Cites] Postgrad Med J. 1974 Jan;50(579):41-4 [4464500.001]
  • [Cites] Chirurg. 1976;47(2):74-8 [964064.001]
  • [Cites] Am Surg. 1977 Apr;43(4):203-7 [851291.001]
  • [Cites] Rofo. 1979 Mar;130(3):370-1 [155586.001]
  • [Cites] Gastrointest Radiol. 1980 Apr 30;5(2):117-9 [7380151.001]
  • [Cites] N Y State J Med. 1980 May;80(6):968-70 [6772998.001]
  • [Cites] J Thorac Cardiovasc Surg. 1981 Jul;82(1):83-7 [7242137.001]
  • [Cites] Am Heart J. 1983 Jan;105(1):148-50 [6849228.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jul;141(1):177-9 [6602516.001]
  • [Cites] Gastrointest Endosc. 1996 Feb;43(2 Pt 1):165-7 [8635717.001]
  • [Cites] AMA J Dis Child. 1957 Mar;93(3):308-12 [13402334.001]
  • [Cites] J Thorac Surg. 1957 Aug;34(2):173-6 [13449942.001]
  • (PMID = 19580643.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2712474
  •  go-up   go-down


74. Melstrom LG, Bentrem DJ, Salvino MJ, Blum MG, Talamonti MS, Printen KJ: Adenocarcinoma of the gastroesophageal junction after bariatric surgery. Am J Surg; 2008 Jul;196(1):135-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the gastroesophageal junction after bariatric surgery.
  • METHODS: A retrospective review was conducted to identify patients who had undergone bariatric surgery (1999 to 2006) and who later developed high-grade dysplasia or adenocarcinoma of the distal esophagus.
  • CONCLUSIONS: Our findings emphasize the importance of precise endoscopic evaluation before bariatric surgery in patients with gastroesophageal reflux disease (GERD), of the necessity for continuing postsurgical surveillance in patients with known Barrett's esophagitis, and of early evaluation in patients who develop new symptoms of GERD after bariatric surgery.
  • [MeSH-major] Adenocarcinoma / etiology. Bariatric Surgery. Esophageal Neoplasms / etiology. Esophagogastric Junction. Postoperative Complications
  • [MeSH-minor] Aged. Barrett Esophagus / etiology. Gastroesophageal Reflux / etiology. Humans. Male. Middle Aged. Obesity, Morbid / complications. Obesity, Morbid / surgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417085.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E: Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol; 2009 Feb;16(2):304-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection.
  • The surgical strategy for adenocarcinoma of the esophagogastric junction is still controversial.
  • The aim of this study was to evaluate surgical results of the abdominal-transhiatal approach for 100 consecutively operated type II and III cardia adenocarcinoma, to clarify clinicopathological differences between these tumors, and to define prognostic factors.
  • A prospectively maintained database identified 100 consecutively operated patients with Siewert type II and III cardia adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Jul;16(7):2074-5; author reply 2076 [19365623.001]
  • (PMID = 19050964.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Gretschel S, Schlag PM: Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach. Recent Results Cancer Res; 2010;182:107-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of sentinel lymph node biopsy in adenocarcinoma of the distal esophagus, gastric cardia, and proximal stomach.
  • The resection of the adenocarcinoma of the esophagogastric junction should be considered to the extent of the lymphatic drainage.
  • As an adenocarcinoma of the esophagogastric junction is located along the borderline between two visceral cavities (mediastinal/abdominal), it can, in principle, metastasize in both cavities.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Esophageal Neoplasms / pathology. Sentinel Lymph Node Biopsy / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676875.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


77. Williams VA, Peters JH: Adenocarcinoma of the gastroesophageal junction: benefits of an extended lymphadenectomy. Surg Oncol Clin N Am; 2006 Oct;15(4):765-80
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the gastroesophageal junction: benefits of an extended lymphadenectomy.
  • The incidence of esophageal adenocarcinoma is rising faster the any other cancer in the United States.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagogastric Junction / surgery. Lymph Node Excision

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030272.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


78. Crane SJ, Locke GR 3rd, Harmsen WS, Diehl NN, Zinsmeister AR, Melton LJ 3rd, Romero Y, Talley NJ: Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol; 2007 Aug;102(8):1596-602
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsite-specific risk factors for esophageal and gastric adenocarcinoma.
  • BACKGROUND: The incidence rates of adenocarcinoma involving specific gastric and esophageal subsites are changing significantly, but the risk factors associated with those subsite changes remain controversial.
  • We aimed to describe the site-specific risk factors associated with adenocarcinoma of the stomach and esophagus.
  • METHODS: Using the Rochester Epidemiology Project, all cases of gastric and esophageal adenocarcinoma among Olmsted County, Minnesota, residents first diagnosed between 1971 and 2000 were identified.
  • RESULTS: A total of 186 incident cases of gastric or esophageal adenocarcinoma were identified between 1971 and 2000, in Olmsted County.
  • Gastroesophageal reflux disease (GERD) was a significant risk factor for both esophageal (OR 5.5, 95% CI 1.2-25) and esophagogastric junction adenocarcinoma (OR 13.0, 95% CI 1.7-99), but not for either proximal or distal gastric cancer.
  • Adenocarcinoma of the junction is probably a form of esophageal cancer and should not be coded with gastric neoplasms.
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Stomach Neoplasms / etiology
  • [MeSH-minor] Aged. Esophagogastric Junction. Female. Gastroesophageal Reflux / complications. Humans. Male. Proton Pump Inhibitors. Risk Factors. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2008 Feb;103(2):492-3 [18289219.001]
  • (PMID = 17459024.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


79. Chak A, Falk G, Grady WM, Kinnard M, Elston R, Mittal S, King JF, Willis JE, Kondru A, Brock W, Barnholtz-Sloan J: Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction. Am J Gastroenterol; 2009 Aug;104(8):1913-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the esophagus and gastroesophageal junction.
  • OBJECTIVES: Adenocarcinomas of the esophagus and adenocarcinomas of the gastroesophageal junction are postulated to be complex genetic diseases.
  • METHODS: A structured validated questionnaire was utilized to collect self-reported data on gastro-esophageal reflux symptoms, risk factors for Barrett's esophagus (BE) and family history, including age of cancer diagnosis in affected relatives from probands with BE, adenocarcinoma of the esophagus, or adenocarcinoma of the gastroesophageal junction, at five tertiary care academic hospitals.
  • Familiality of BE/cancer, obesity (defined as body mass index >30), gastroesophageal reflux symptoms, and other risk factors were assessed for association with a young age of cancer diagnosis.
  • There were also no significant differences in symptoms of gastroesophageal reflux, body mass index, race, gender, and smoking history between familial and non-familial cancers.
  • CONCLUSIONS: Obesity is associated with the development of esophageal and gastroesophageal junctional adenocarcinomas at an earlier age.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / genetics. Esophagogastric Junction. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Gut. 2002 Sep;51(3):323-8 [12171951.001]
  • [Cites] JAMA. 2003 Jul 2;290(1):66-72 [12837713.001]
  • [Cites] Int J Epidemiol. 2003 Aug;32(4):645-50 [12913045.001]
  • [Cites] J Med Genet. 2003 Sep;40(9):651-6 [12960209.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] N Engl J Med. 1986 Aug 7;315(6):362-71 [2874485.001]
  • [Cites] Gastroenterology. 1987 Jan;92(1):118-24 [3781178.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Gastroenterology. 1989 May;96(5 Pt 1):1249-56 [2703113.001]
  • [Cites] Am J Clin Nutr. 1990 Dec;52(6):1125-33 [2239790.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1212-9 [1551528.001]
  • [Cites] Gastroenterology. 1992 Oct;103(4):1241-5 [1397881.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] Mayo Clin Proc. 1994 Jun;69(6):539-47 [8189759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):847-8 [7791237.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1541-6 [7557137.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):277-85 [9922307.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Am J Med. 1999 Jun;106(6):642-9 [10378622.001]
  • [Cites] Am J Gastroenterol. 2004 Nov;99(11):2107-14 [15554988.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2151-6 [16181362.001]
  • [Cites] Scand J Gastroenterol. 2005 Sep;40(9):1127-8 [16211720.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1668-73 [16985029.001]
  • [Cites] Dis Esophagus. 2007;20(1):53-7 [17227311.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):34-41; quiz 311 [17631128.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):403-11 [17681161.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2520-8 [10861428.001]
  • (PMID = 19491834.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024989; United States / NIDDK NIH HHS / DK / R01 DK070863-03; United States / NIDDK NIH HHS / DK / R01 DK070863; United States / NCRR NIH HHS / RR / M01 RR00080; United States / NIDDK NIH HHS / DK / K24 DK002800-08; United States / NIDDK NIH HHS / DK / R01DK070863; United States / NIDDK NIH HHS / DK / K24 DK002800; United States / NCRR NIH HHS / RR / M01 RR000080; United States / NIDDK NIH HHS / DK / K24DK002800
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS194150; NLM/ PMC2864226
  •  go-up   go-down


80. DeMeester SR: Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol; 2006 Jan;13(1):12-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment.
  • Previously rare, adenocarcinoma of the esophagus and gastroesophageal junction is now the most common esophageal cancer, and in the United States the incidence is increasing faster than that of any other malignancy.
  • Surveillance in patients with Barrett's esophagus is identifying adenocarcinoma at an earlier, more curable stage in many patients, and at the same time new endoscopic and surgical options are available for the therapy of these localized tumors.
  • METHODS: This article is a review of the epidemiology, diagnosis, staging, and treatment options for esophageal and gastroesophageal junction adenocarcinoma.
  • RESULTS: The epidemiology, prognosis, patterns of lymphatic metastasis, and survival for esophageal and gastroesophageal junction adenocarcinoma suggest that these tumors are similar.
  • CONCLUSIONS: Surveillance programs for Barrett's are identifying patients with early, curable adenocarcinoma of the esophagus or gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16378161.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 163
  •  go-up   go-down


81. Wilke H, Stahl M: [Therapy in gastric cancer. From an oncological perspective]. Chirurg; 2009 Nov;80(11):1023-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In two randomized trials it was demonstrated that preoperative and postoperative chemotherapy shows a statistically significant and clinically relevant improvement in progression-free and overall survival for adenocarcinoma of the esophagogastric junction and stomach when compared with the surgical control arm.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902288.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 18
  •  go-up   go-down


82. Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, Wang X, Gao G, Wu TT, Komaki R, Chang JY: Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys; 2007 Feb 1;67(2):389-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma.
  • PURPOSE: To clarify the radiotherapy clinical target volume (CTV) margin needed for esophageal squamous-cell carcinoma (SCC) and gastroesophageal junction (GEJ) adenocarcinoma.
  • METHODS AND MATERIALS: Surgical specimens of esophageal SCC (n = 34) and GEJ adenocarcinoma (n = 32) were prospectively collected and analyzed for microscopic spread along the esophagus and GEJ both proximally and distally from gross tumor and for lymph node (LN) metastasis.
  • For GEJ adenocarcinoma, the spread was 10.3 +/- 7.2 mm proximally (<30 mm in 29 of 29 cases) and 18.3 +/- 16.3 mm distally (<30 mm in 27 of 32 cases).
  • LN metastases were observed in 12 (35%) of 34 patients with middle and lower esophageal SCC and 15 (47%) of 32 patients with GEJ adenocarcinoma.
  • CONCLUSIONS: The extent of microscopic spread within esophagus (recommended CTV margin) was <30 mm in about 94% of cases of esophageal cancer, except for distal microscopic spread in GEJ adenocarcinoma, in which 50 mm was needed to cover about 94% of cases.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236963.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Norris WE, Perry JL, Moawad FJ, Horwhat JD: An unusual presentation of metastatic esophageal adenocarcinoma presenting as thigh pain. J Gastrointestin Liver Dis; 2009 Sep;18(3):371-4
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic esophageal adenocarcinoma presenting as thigh pain.
  • The association between esophageal adenocarcinoma and distant skeletal muscle metastasis is extremely rare.
  • All reported involvement of the gastroesophageal junction.
  • Endoscopic biopsy showed poorly differentiated adenocarcinoma.
  • Final diagnosis was primary esophageal adenocarcinoma with distant metastasis to the right ileum and iliacus muscle.
  • We review distinctions between esophageal adenocarcinoma and adenocarcinoma of the gastroesophageal junction.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Muscle, Skeletal / pathology. Pain / etiology
  • [MeSH-minor] Endosonography. Esophagogastric Junction / pathology. Humans. Male. Middle Aged. Thigh. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795036.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


84. Gillen S, Friess H, Kleeff J: Palliative cardia resection with gastroesophageal reconstruction for perforated carcinoma of the gastroesophageal junction. World J Gastroenterol; 2009 Jun 28;15(24):3065-7
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative cardia resection with gastroesophageal reconstruction for perforated carcinoma of the gastroesophageal junction.
  • Iatrogenic perforation of esophageal cancer or cancer of the gastroesophageal (GE) junction is a serious complication that, in addition to short term morbidity and mortality, significantly compromises the success of any subsequent oncological therapy.
  • Here, we present an 82-year-old man with iatrogenic perforation of adenocarcinoma of the GE junction.
  • Immediate surgical intervention included palliative resection and GE reconstruction.
  • [MeSH-major] Cardia / surgery. Esophageal Neoplasms. Esophageal Perforation / surgery. Esophagogastric Junction. Palliative Care. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2005 Feb 15;21(4):479-84 [15710000.001]
  • [Cites] Ann Surg. 2005 Jun;241(6):1016-21 ;discussion 1021-3 [15912051.001]
  • [Cites] Am J Surg. 2005 Aug;190(2):161-5 [16023423.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(4):767-87 [16997159.001]
  • [Cites] Br J Surg. 2008 Jul;95(7):837-9 [18457352.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(5):959-78 [16997172.001]
  • [Cites] Surg Today. 2006;36(10):874-8 [16998680.001]
  • [Cites] World J Surg. 2008 Jul;32(7):1473-7 [18264827.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(5):843-66 [16997165.001]
  • (PMID = 19554663.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2702118
  •  go-up   go-down


85. Villwock Mde M, Meurer L, Cavazzola LT, Gurski RR, Edelweiss MI, Schirmer CC: Prevalence of p21 immunohistochemical expression in esophageal adenocarcinoma. Arq Gastroenterol; 2006 Jul-Sep;43(3):212-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of p21 immunohistochemical expression in esophageal adenocarcinoma.
  • BACKGROUND: In western societies, the prevalence of adenocarcinoma of the gastroesophageal junction has increased in recent years.
  • It is commonly accepted today that esophageal adenocarcinoma develops from a premalignant lesion: Barrett's esophagus.
  • AIM: To check the prevalence of p21 protein expression in patients with esophageal adenocarcinoma diagnosed in the last 5 years by the Group for Surgeries of the Esophagus and Stomach of "Hospital de Clínicas de Porto Alegre", RS, Brazil.
  • METHODS: The study population consisted of 42 patients with esophageal adenocarcinoma diagnosed by the Group for Surgeries of the Esophagus and Stomach between January 1998 and December 2002.
  • CONCLUSION: p21 was expressed in 9 of 42 patients (21.4%) with esophageal adenocarcinoma diagnosed in the last 5 years by the Group for Surgeries of the Esophagus and Stomach of Hospital de Clínicas de Porto Alegre.
  • In our patient population, the accumulation of p21 did not play a key role in the carcinogenesis of esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Esophageal Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160237.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21
  •  go-up   go-down


86. Kojima T, Matsui T, Uemura T, Fujimitsu Y, Kure N, Mochizuki Y, Kojima H: [A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1923-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
  • We report a 63-year-old man with recurrent gastroesophageal junction adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Drug Combinations. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / radiotherapy. Esophageal Neoplasms / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011344.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


87. Azatian A, Yu H, Dai W, Schneiders FI, Botelho NK, Lord RV: Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas. J Gastrointest Surg; 2009 Jun;13(6):1044-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.
  • This study investigated the effectiveness of HSV-tk activation as gene therapy for gastroesophageal junction and gastric adenocarcinomas using either the stress-inducible Grp78 promoter or the murine leukemia virus long-terminal repeat (LTR) promoter.
  • METHODS: The HSV-tk gene, controlled by either the Grp78 promoter or the LTR promoter, was transduced into the gastroesophageal junction adenocarcinoma cell line SK-GT-5 and the gastric adenocarcinoma cell line MKN-74.
  • CONCLUSION: HSV-tk xwith ganciclovir suicide gene therapy results in significant cell killing in gastroesophageal junction and gastric adenocarcinoma cells both in vitro and in vivo, but complete tumor elimination only occurred with the gastric adenocarcinoma cell tumors.
  • [MeSH-major] Adenocarcinoma / therapy. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Heat-Shock Proteins / genetics. Stomach Neoplasms / therapy. Thymidine Kinase / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277794.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Heat-Shock Proteins; 0 / molecular chaperone GRP78; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


88. Yuasa N, Miyake H, Yamada T, Ebata T, Nimura Y, Hattori T: Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction. World J Surg; 2006 Mar;30(3):364-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction.
  • BACKGROUND: Since Misumi et al. and Siewert proposed a new classification for carcinoma of the gastroesophageal junction (GEJ), few surgical studies using these criteria have been reported from Eastern countries.
  • We set out to determine whether type II adenocarcinoma is a distinct clinical entity requiring a more specific treatment plan.
  • METHODS: Among 125 Japanese patients who underwent resection of adenocarcinoma of the GEJ (type I, 2; type II, 44; type III, 79), 101 who underwent R0 resections (type II, 40; type III, 61) were analyzed to evaluate surgical results and compare clinicopathologic factors.
  • RESULTS: Barrett's epithelium was recognized in two patients with type II adenocarcinoma.
  • Siewert type II adenocarcinoma differs sufficiently to be considered a clinical entity distinct and independent from type III.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485063.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Wilson M, Rosato EL, Chojnacki KA, Chervoneva I, Kairys JC, Cohn HE, Rosato FE Sr, Berger AC: Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res; 2008 May 1;146(1):11-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The incidence of carcinoma of the distal esophagus and GE junction is rapidly increasing.
  • The largest number of patients (45%) had adenocarcinoma of the GE junction; 29% of patients had esophageal adenocarcinoma while 14% had squamous cell cancer of the esophagus.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2002 Sep;236(3):376-84; discussion 384-5 [12192324.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1434-43 [12237911.001]
  • [Cites] Surg Clin North Am. 2002 Aug;82(4):729-46 [12472127.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] J Surg Oncol. 2006 Oct 1;94(5):355-63 [16967455.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 May;117(5):960-8 [10220691.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Mar;115(3):660-69; discussion 669-70 [9535455.001]
  • (PMID = 18028955.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA069277-06; United States / NCI NIH HHS / CA / R25 CA069277; United States / NCI NIH HHS / CA / CA069277; United States / NCI NIH HHS / CA / R25 CA069277-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS45990; NLM/ PMC2323456
  •  go-up   go-down


90. Marano S, Ruol A, Castoro C, Portale G, Cagol M, Alfieri R, Michieletto S, Ancona E: Adenocarcinoma of the proximal esophagus: report of 9 patients and review of the literature. Ann Surg Oncol; 2008 Oct;15(10):2910-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the proximal esophagus: report of 9 patients and review of the literature.
  • BACKGROUND: Adenocarcinoma of the proximal esophagus is a rare clinical entity, with only 28 cases described in the literature.
  • METHODS: Between 1980 and 2004, 1010 patients with esophageal or gastroesophageal junction adenocarcinoma (from a total of 4655 cancers, 3510 squamous and 1145 adeno) presenting at our department were retrospectively evaluated.
  • RESULTS: Nine patients (0.9%) had adenocarcinoma located in the proximal esophagus.
  • CONCLUSION: First-line chemoradiotherapy is an effective treatment for adenocarcinoma of the proximal esophagus.
  • [MeSH-major] Esophageal Neoplasms / pathology. Esophagectomy. Esophagogastric Junction / pathology. Salvage Therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696159.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. van Duin M, van Marion R, Vissers KJ, Hop WC, Dinjens WN, Tilanus HW, Siersema PD, van Dekken H: High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas. Cytogenet Genome Res; 2007;118(2-4):130-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas.
  • Amplification of 8q is frequently found in gastroesophageal junction (GEJ) cancer.
  • It is usually detected in high-grade, high-stage GEJ adenocarcinomas.
  • In this study, a detailed genomic analysis of 8q was performed on a series of GEJ adenocarcinomas, including 22 primary adenocarcinomas, 13 cell lines and two xenografts, by array comparative genomic hybridization (aCGH) with a whole chromosome 8q contig array.
  • Quantitative RT-PCR analysis of these seven genes was subsequently performed on a panel of 24 gastroesophageal samples, including 13 cell lines, two xenografts and nine normal stomach controls.
  • Significant overexpression was found for MYC and EXT1 in GEJ adenocarcinoma cell lines and xenografts compared to normal controls.
  • We conclude that, firstly, there are other genes than MYC involved in the 8q amplification in GEJ cancer.
  • Secondly, the differential expression of these genes contributes to unravel the biology of GEJ adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 8. Esophageal Neoplasms / genetics. Esophagogastric Junction / pathology. Nucleic Acid Conformation. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000363.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


92. Bain GH, Petty RD: Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist; 2010;15(3):270-84
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers.
  • The incidence of adenocarcinomas of the gastroesophageal junction (GEJ) is rapidly rising, and even in early-stage locoregional confined disease the 5-year survival rate rarely exceeds 25%-35%.
  • These clinical data provide a strong argument for the urgent development of methods to predict histopathological response to neoadjuvant therapies for GEJ adenocarcinoma.
  • This review presents the evidence base and discusses novel experimental approaches for the combination of biomarker modalities to allow optimization of an individualized treatment approach in GEJ adenocarcinoma patients that may be relevant to other tumor types as well.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / drug therapy. Esophagogastric Junction / pathology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3460-9 [17575208.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):191-7 [17638652.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1925-32 [17680242.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Eur J Cancer. 2008 Jan;44(2):182-94 [18093827.001]
  • [Cites] Gut. 2008 Mar;57(3):298-305 [17965056.001]
  • [Cites] Br J Pharmacol. 2008 Feb;153(4):646-56 [17876307.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1408-17 [18374226.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(13):1807-19 [18640028.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):836-7 [19139425.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):851-6 [19139439.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):878-86 [19194759.001]
  • [Cites] Gastroenterology. 2009 Apr;136(4):1215-24, e1-2 [19250648.001]
  • [Cites] Ann Oncol. 2009 May;20(5):885-91 [19164454.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] Surg Today. 2005;35(1):7-18 [15622457.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2215-21 [15788669.001]
  • [Cites] World J Surg. 2005 Jan;29(1):39-45 [15599738.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1241-6 [15870949.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] AJR Am J Roentgenol. 2005 Aug;185(2):436-40 [16037517.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4 [16106022.001]
  • [Cites] Radiology. 2005 Sep;236(3):841-51 [16118165.001]
  • [Cites] Dis Esophagus. 2005;18(4):246-52 [16128781.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7462-9 [16243820.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):259-67 [16344314.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):748-54 [16401681.001]
  • [Cites] Cancer. 2006 May 15;106(10):2119-27 [16607651.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 May;18(4):345-50 [16703754.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3282-92 [16829652.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Oct;126(10):549-59 [11043392.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):562-9 [11297249.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3058-65 [11408502.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):360-7; discussion 368-9 [11524589.001]
  • [Cites] Chest. 2001 Nov;120(5):1584-91 [11713138.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Apr;21(4):657-63 [11932164.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):361-8 [11996465.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):77-86; discussion 86-7 [12559188.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):682-8 [12601498.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2651-7 [12860940.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Mol Imaging Biol. 2003 Sep-Oct;5(5):337-46 [14630513.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6461-8 [14695149.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):199-204 [14760668.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):491-500 [15024310.001]
  • [Cites] Oncologist. 2004;9(2):137-46 [15047918.001]
  • [Cites] Eur J Surg Oncol. 2004 Jun;30(5):544-50 [15135484.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3794-9 [15173087.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):666-72 [15213712.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1776-85 [15386332.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 [6577010.001]
  • [Cites] Jpn J Surg. 1989 May;19(3):290-5 [2779027.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 16;88(20):1456-66 [8841020.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1026-32 [10091784.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1174-9 [17024121.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2844-50 [17121931.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):120-9 [17143264.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):38-44 [17185196.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):58-64 [17197919.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):405-9 [17097832.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1160-8 [17401004.001]
  • (PMID = 20203174.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CZB/4/747
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 88
  • [Other-IDs] NLM/ PMC3227948
  •  go-up   go-down


93. Büyükçelik A, Onur H, Akbulut H, Bülent Y, Ensari A, Utkan G, Onal BS, Içli F: Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori; 2005 Jul-Aug;91(4):302-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
  • AIMS AND BACKGROUND: We evaluated the prognostic value of p53 protein, DNA content and S-phase fraction in patients with adenocarcinoma of the stomach or the gastroesophageal junction treated with adjuvant etoposide, doxorubicin and cisplatin.
  • METHODS AND STUDY DESIGN: Thirty-five consecutive patients with stage II or III gastric or gastroesophageal junction adenocarcinoma treated with at least two cycles of adjuvant etoposide, doxorubicin and cisplatin after curative gastric resection were included.
  • CONCLUSIONS: This trial supports the results of previous reports that p53 immunoreactivity is a prognostic factor for patients with adenocarcinoma of stomach or gastroesophageal junction treated with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Flow Cytometry. Stomach Neoplasms / drug therapy. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Esophagogastric Junction. Etoposide / administration & dosage. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Ploidies. Predictive Value of Tests. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277093.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


94. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol; 2006 Oct 20;24(30):4922-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
  • PURPOSE: A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: gastroesophageal junction (GEJ)/cardia and distal gastric adenocarcinomas.
  • PATIENTS AND METHODS: Patients with a histologically proven diagnosis of adenocarcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disease; no prior chemotherapy for advanced or metastatic cancer; Zubrod performance status (PS) of 0 to 1; and adequate renal, hepatic, and hematologic function were treated with erlotinib 150 mg/d orally.
  • Patient characteristics were median age, GEJ-63 years, ST-64 years; sex, GEJ-84% male and 16% female, ST-60 male and 40 female; Zubrod PS, GEJ-25 had a PS of 0 and 18 had a PS 1, ST-13 had a PS of 0 and 12 had a PS of 1.
  • RESULTS: Percentage of common toxicities were skin rash, 86% and 72%; fatigue, 51% and 44%; and AST/ALT elevation, 28% and 28%, respectively for GEJ and ST.
  • There has been one confirmed complete response, three confirmed partial responses (PRs) and one unconfirmed PR for an overall response probability of 9% confirmed (95% CI, 3% to 22%), all occurring in GEJ stratum.
  • The median survival was 6.7 months in GEJ and 3.5 months in ST stratum.
  • CONCLUSION: Erlotinib is active in patients with GEJ adenocarcinomas, but appears inactive in gastric cancers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):910; author reply 911 [17327617.001]
  • [ErratumIn] J Clin Oncol. 2007 Jun 1;25(16):2334
  • (PMID = 17050876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


95. van Dekken H, Tilanus HW, Hop WC, Dinjens WN, Wink JC, Vissers KJ, van Marion R: Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. Cancer Genet Cytogenet; 2009 Feb;189(1):37-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction.
  • Survival rates of adenocarcinomas of the gastroesophageal junction (GEJ) are low, because these tumors are generally in an advanced stage by the time they are detected.
  • Chromosomal regions 1q32, 7q21, and 8p22 display critical alterations in GEJ cancers; however, the genes underlying alterations in these genomic areas are largely unknown.
  • To delineate overexpressed genes, we performed array comparative genomic hybridization (aCGH) and mRNA expression analysis of 15 GEJ adenocarcinoma samples using a fine-tiling cDNA array covering chromosome segments 1q31.3~q41 (193.9-215.8 Mb: 21.9 Mb), 7q11.23~q22.1 (72.3-103.0 Mb: 30.7 Mb), and 8p23.1~p21.3 (11.1-20.7 Mb: 9.6 Mb).
  • In conclusion, using a straightforward approach we constructed a targeted gene profile for GEJ adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 8 / genetics. Esophageal Neoplasms / genetics. Esophagogastric Junction / metabolism. Stomach Neoplasms / genetics


96. Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L, Ivy SP, Remick SC: A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol; 2009 Apr;63(5):851-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
  • BACKGROUND: There is no standard first-line therapy for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma and the prognosis remains poor.
  • We performed a phase II trial in advanced gastric and GEJ adenocarcinoma to determine response rate and response duration.
  • CONCLUSIONS: Oxaliplatin, irinotecan, and capecitabine given in a novel, weekly schedule does induce responses in advanced gastric and GEJ adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670776.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062502; United States / NCI NIH HHS / CA / U01 CA62502
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS634366; NLM/ PMC4209292
  •  go-up   go-down


97. Beer AJ, Wieder HA, Lordick F, Ott K, Fischer M, Becker K, Stollfuss J, Rummeny EJ: Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology; 2006 May;239(2):472-80
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy.
  • PURPOSE: To prospectively evaluate multi-detector row computed tomography (CT) in the assessment of early response during neoadjuvant chemotherapy for adenocarcinoma of the esophagogastric junction (AEG).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiography. Esophageal Neoplasms / radiography. Esophageal Neoplasms / radiotherapy. Esophagogastric Junction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • (PMID = 16543584.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Zhao X, Sandhu B, Kiev J: Colobronchial fistula as a rare complication of coloesophageal interposition: a unique treatment with a review of the medical literature. Am Surg; 2005 Dec;71(12):1058-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had previously undergone esophagectomy for adenocarcinoma of the gastroesophageal junction.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colon / physiopathology. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / radiography. Postoperative Complications / surgery. Rare Diseases. Risk Assessment. Stents. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447480.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


99. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ: Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol; 2007 Feb;14(2):977-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction.
  • OBJECTIVE: This review describes genetic and molecular changes related to adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) with emphasis on prognostic value and possibilities for targeted therapy in clinical setting.
  • Adenocarcinoma of the esophagus or GEJ is an aggressive disease with early lymphatic and hematogenous dissemination.
  • METHODS: A review of recent English literature (1990-October 2005) concerning esophageal adenocarcinoma was performed.
  • This review focuses on genetic and molecular changes as prognosticators of adenocarcinoma of the esophagus and GEJ.
  • CONCLUSIONS: Adenocarcinomas of the esophagus and GEJ show multiple genetic alterations, which indicate that progression of cancer is a multistep complex process with many different alterations.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Esophageal Neoplasms / genetics. Esophagogastric Junction


100. Lerut T, Decker G, Coosemans W, De Leyn P, Decaluwé H, Nafteux P, Van Raemdonck D: Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction. Recent Results Cancer Res; 2010;182:127-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction.
  • Surgical treatment of adenocarcinoma of the esophagus and gastroesophageal junction is complex and challenging.
  • Definition of the gastroesophageal junction remains controversial and the performance of staging procedures i.e.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676877.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement